IN8bio, Inc. to Post Q1 2024 Earnings of ($0.15) Per Share, Zacks Small Cap Forecasts (NASDAQ:INAB)

IN8bio, Inc. (NASDAQ:INAB) – Research analysts at Zacks Small Cap issued their Q1 2024 EPS estimates for shares of IN8bio in a research note issued to investors on Monday, April 22nd. Zacks Small Cap analyst J. Vandermosten anticipates that the company will earn ($0.15) per share for the quarter. The consensus estimate for IN8bio’s current full-year earnings is ($0.70) per share. Zacks Small Cap also issued estimates for IN8bio’s Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.58) EPS, FY2025 earnings at ($0.59) EPS and FY2026 earnings at ($0.60) EPS.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.05).

Several other brokerages have also recently issued reports on INAB. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of IN8bio in a research report on Wednesday, April 10th. Laidlaw assumed coverage on shares of IN8bio in a research note on Monday, March 18th. They issued a “buy” rating and a $7.50 price objective on the stock.

IN8bio Stock Up 4.0 %

Shares of NASDAQ INAB opened at $1.04 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.57 and a current ratio of 4.57. IN8bio has a 52-week low of $0.65 and a 52-week high of $3.95. The firm has a 50 day moving average price of $1.13 and a two-hundred day moving average price of $1.16.

Institutional Investors Weigh In On IN8bio

A number of institutional investors have recently modified their holdings of INAB. Voss Capital LLC boosted its stake in shares of IN8bio by 11.7% in the 3rd quarter. Voss Capital LLC now owns 511,584 shares of the company’s stock valued at $532,000 after purchasing an additional 53,708 shares during the last quarter. Rock Creek Group LP boosted its stake in IN8bio by 98.3% during the third quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock worth $157,000 after acquiring an additional 75,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its stake in IN8bio by 85.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 78,624 shares of the company’s stock worth $109,000 after acquiring an additional 36,179 shares in the last quarter. Finally, AIGH Capital Management LLC bought a new position in IN8bio during the fourth quarter worth $5,216,000. 92.05% of the stock is owned by institutional investors.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.